Print

AVEG 027

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternative Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) November 03, 1999
ALVAC-HIV MN120TMG strain (vCP205) Canarypox Env gp120, TM gp41, gag, protease B MN/LAI
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 84
NCT00000884
http://www.clinicaltrials.gov/ct2/show/NCT00000884